NIH Must Meet the Hughes Challenge

For the past 30 years the forefront of biomedical research has been synonymous with the efforts of the U.S. research community, shaped and financed by the National Institutes of Health (NIH). Now NIH's pre-eminence is at risk, challenged by the emergence of the Howard Hughes Medical Institute (HHMI) as a leader in the field. Since 1985, HHMI—with assets of $45.2 billion—has spent the better part of $485.4 million at 48 academic centers. Hughes researchers, many of them former stars o

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Since 1985, HHMI—with assets of $45.2 billion—has spent the better part of $485.4 million at 48 academic centers. Hughes researchers, many of them former stars of NIH extramural programs, have quickly formed a new elite, and the reason is clear: Hughes provides generous funding and requires minimal paperwork, thus freeing a scientist for research. A recent ruling by the Internal Revenue Service will now extend the Hughes largess to an increasing number of scientists (see The Scientist, January 26, 1987, pp. 16-17 and March 23, 1987, p. 3). With such good news, what can the bad news be?

It may lie in answer to the questions "Will support for the best science and the establishment of the biomedical agenda shift from the public to the private sector?" and "Will public oversight of biomedical research be lost?"

NIH's history of setting standards for excellence can be attributed to two closely linked ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Sandra Panem

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio